A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
NCT00091624
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
77
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
CC-5013
Sponsor
Celgene Corporation